Paulo Falabella
Company: REGENXBIO
Job title: Vice President - Clinical Development & Operations
Seminars:
Initiating Clinical Trials with Gene Therapies Targeting Neurodegenerative Disorders 11:45 am
Clinical Experience with AAV9-based Gene Therapies Targeting Neurodegenerative Disorders Interim analysis of the RGX-121 gene therapy first in human study for the treatment of severe Mucopolysaccharidosis Type II Interim analysis of the RGX-111 gene therapy first in human study and a single patient IND for the treatment of severe Mucopolysaccharidosis Type IRead more
day: Day Two